Enrollment goal: 10 Primary investigator: Juan Ibla, MD Contact: Carolyn Dunbar-Masterson, RN: Carolyn. Faraoni D, Gardella KM, Odegard KC, Emani SM, Di Nardo JA.
Enrollment goal: 250 Primary investigator: Juan Ibla, MD Contact: Bre Piekarski, RN, BSN: Breanna.Enrollment goal: 300 Primary investigators: Mary Mullen MD, Ph D and Thomas Kulik MD Contact: Jessica Mecklosky: Jessica. Catheter ablation for atrioventricular nodal reentrant tachycardia in patients with congenital heart disease. [email protected] 617-919-4456 Title: Neurocognitive Function of Adolescents and Young Adults with Repaired Complex Congenital Heart Disease after Recent Cardiac Re-Interventions: A Pilot Study Description: The goal of this study is to determine the impact on neurocognitive function for patients with repaired complex congenital heart disease who are scheduled for right ventricular outflow tract re-intervention for patients undergoing surgical or transcatheter pulmonary valve replacement. VKA or LMWH in Pediatric Subjects with Congenital or Acquired Heart Disease on Chronic Anticoagulation for Thromboembolism Prevention Description: This is a multi-center, randomized trial designed to assess the safety and pharmacokinetics of the anticoagulation agent Apixaban compared to conventional anticoagulation drugs in children with acquired and congenital heart disease. Mah DY, Cheng H, Alexander ME, Sleeper L, Newburger JW, del Nido PJ, Thiagarajan RR, Rajagopal SK. Correlates of Achieving Statin Therapy Goals in Children and Adolescents with Dyslipidemia.
At Boston Children’s Hospital, up to 40 children between 2 to Title: Pharmacodynamics, Pharmacokinetics, Safety and Efficacy of Rivaroxaban for Thromboprophylaxis in Pediatric Subjects 2 to 8 Years of Age after the Fontan Description: This prospective, open label active controlled multi-center study is tasked with the goal to evaluate the safety and optimal dosing of rivaroxaban (an oral anticoagulation agent) compared to acetylsalicylic acid for thrombus prevention in children aged 2 to 8 years with single ventricle physiology who have completed the Fontan procedure. Lin Z, Guo H, Cao Y, Zohrabian S, Zhou P, Ma Q, Van Dusen N, Guo Y, Zhang J, Stevens SM, Liang F, Quan Q, van Gorp PR, Li A, Dos Remedios C, He A, Bezzerides VJ, Pu WT. Acetylation of VGLL4 Regulates Hippo-YAP Signaling and Postnatal Cardiac Growth. Heart block following stage 1 palliation of hypoplastic left heart syndrome. Enrollment goal: 20 Primary investigator: Lisa Bergersen, MD MPH Contact: Priscila Cevallos and Andi Goodman: Cardio [email protected]: New Enrollment SAPIEN XT Post-Approval Study (COMPASSION XT PAS) Description: The goal of this study is to evaluate the safety of the FDA-approved SAPIEN XT THV in the approved pulmonic position.